Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27653228 | 0.88 | CNR1 (0.50) | CNR1 | |
| SCHEMBL12918610 | 0.86 | CNR2 (0.59) | CNR1 | |
| SCHEMBL27673220 | 0.86 | CNR1 (0.50) | CNR1 | |
| SCHEMBL4692303 | 0.83 | CNR1 (0.48) | CNR1 | |
| SCHEMBL2679126 | 0.83 | CNR1 (0.65) | CNR1 | |
| SCHEMBL972018 | 0.83 | CNR1 (0.51) | CNR1 | |
| SCHEMBL974512 | 0.82 | PDE4B (0.54) | CNR1 | |
| SCHEMBL5484151 | 0.82 | PDE4B (0.54) | CNR1 | |
| SCHEMBL5460970 | 0.81 | CNR1 (0.51) | CNR1 | |
| SCHEMBL702658 | 0.81 | CNR1 (0.48) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CAREX SA (FR) | 2008-08-21 | — | — | US | disclosed |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| CN-1886407-A | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER (US) | 2006-12-27 | — | — | CN | disclosed |
| WO-2006133926-A1 | PYRAZOLE DERIVATES AS CANNABINOID RECEPTOR MODULATORS | CAREX SA (FR) | 2006-12-21 | — | — | WO | disclosed |
| US-7151097-B2 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1682554-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | Pfizer Products Incorporated (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006035310-A2 | PROCESS FOR PREPARING BICYCLIC PYRAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005044822-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200527-A1 | Cannabinoid Receptor Modulators | CNR1, CNR2, HCRTR2 | CNR1 1/4885 |
| US-20070027133-A1 | BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | CNR1 1/4885 |
| US-20050101592-A1 | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof | CNR2, CNR1, GPR18 | CNR1 2/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.